Revvity stock kpis
Want to see RVTY full AI Analyst Report?
Revenue by Segment
In Q3 2026, Revvity reported revenue by segment of $379.59M (Life Sciences) and $349.31M (Diagnostics).
Shows total sales for each business segment, identifying which units drive top‑line growth and how balanced the company’s portfolio is. Faster‑growing segments point to future upside, while slow or shrinking segments may require strategic changes or indicate market saturation.
Diagnostics has been the recovery engine since the 2022 trough — steady, double‑digit organic momentum per the call and strong high‑content instrument orders plus Genomics England contribution — while Life Sciences is choppier, pressured by Signals software contract timing and tough comps. Management's upgraded 2026 outlook and the ACD/Labs tuck‑in support the mid-single-digit organic target, but some of Q2's outperformance was one-time (tariff refunds, tax timing) and sustained margin upside depends on a software rebound and resolving instrument production timing.
RVTY Revenue by Segment
| Period | Life Sciences | Diagnostics |
|---|---|---|
| Q3 2026Sep 30, 2026 | $379.59M | $349.31M |
| Q2 2026Jun 30, 2026 | $358.70M | $370.99M |
| Q1 2026Mar 31, 2026 | $361.85M | $349.27M |
| Q4 2025Dec 31, 2025 | $381.99M | $390.07M |
| Q3 2025Sep 30, 2025 | $342.82M | $356.13M |
| Q2 2025Jun 30, 2025 | $365.90M | $354.39M |
| Q1 2025Mar 31, 2025 | $340.39M | $324.37M |
| Q4 2024Dec 31, 2024 | $336.34M | $392.41M |
| Q3 2024Sep 30, 2024 | $300.92M | $383.33M |
| Q2 2024Jun 30, 2024 | $313.85M | $378.05M |
| Q1 2024Mar 31, 2024 | $303.04M | $347.09M |
| Q4 2023Dec 31, 2023 | $319.69M | $376.42M |
| Q3 2023Sep 30, 2023 | $307.86M | $363.09M |
| Q2 2023Jun 30, 2023 | $336.35M | $372.92M |
| Q1 2023Mar 31, 2023 | $328.44M | $346.63M |
| Q4 2022Dec 31, 2022 | $347.43M | $393.99M |
| Q3 2022Sep 30, 2022 | $312.78M | $399.22M |
| Q2 2022Jun 30, 2022 | $326.61M | $569.23M |
| Q1 2022Mar 31, 2022 | $306.09M | $657.28M |
| Q4 2021Dec 31, 2021 | $654.91M | $709.41M |
| Q3 2021Sep 30, 2021 | $512.88M | $653.80M |
| Q2 2021Jun 30, 2021 | $512.83M | $715.64M |
| Q1 2021Mar 31, 2021 | $454.61M | $853.08M |

